Eyecare

NIH researchers have created a 3D map of DNA within human retina cells and identified new gene variants that could be risk factors for age-related macular degeneration and glaucoma.

A bioengineered corneal implant made with collagen from pig’s skin could be an alternative to human transplants for those with keratoconus, a rare condition that can lead to blurry vision and blindness.

For patients with dry eyes, a cross-study comparison finds Tyrvaya may produce more natural tears than Xiidra.

Novaliq’s CyclASol uses the EyeSol technology that allows for improved bioavailability and better efficacy. The PDUFA target action date set by the FDA is June 8, 2023.

The FDA has assigned a target action date of Feb. 11, 2023.

This is the first study to use an artificial intelligence algorithm to break down visual field loss in new-onset glaucoma cases among U.S.-based population groups.

Older patients who had cataract surgery had almost a 30% lower risk of developing dementia compared with those who did not, a recent analysis finds.

Researchers at the National Eye Institute have designed a gene therapy approach that could help prevent blindness in children with Leber congenital amaurosis, a rare form of blindness.

Omlonti is approved to reduce elevated intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension

If approved, NOV03 would be the first prescription eye drop to address excessive tear evaporation. The FDA has assigned a PDUFA action date of June 28, 2023.

A recent literature reviewed showed a plausible link between diabetic retinopathy and the gut microbiome. The authors speculate that the manipulating the makeup of microbiome might be a way to help keep diabetic retinopathy in check.

Even small payments can influence ophthalmologists and optometrists to prescribe branded therapies to treat patients with glaucoma.

Patients who received the chemotherapies paclitaxel and docetaxel were at an increased risk of adverse events of the eye.

Novaliq’s CyclASol uses a new technology that allows cyclosporine to be soluble without water or preservatives.

A meta-analysis has found that depression and anxiety are significantly correlated with dry eye disease symptoms but not to dry eye disease signs.

A literature review finds that glaucoma care changed for the better during the COVID-19 pandemic.

Vabysmo is the first injectable bispecific antibody to treat wet age-related macular degeneration and diabetic macular edema. Some recent data suggests that the injections can be administered less often than first indicated with no loss of efficacy.

Coherus’ Cimerli has been approved to be interchangeable for all five indications, including age-related macular degeneration and diabetic retinopathy. It will be available in early October 2022.

Pegcetacoplan is a targeted therapy to treat patients with age-related macular degeneration. The Prescription Drug User Fee Act (PDUFA) target action date is Nov. 26, 2022.

Those with age-related macular degeneration like the port delivery system for ranibizumab because it requires fewer treatments and there is less discomfort.

Reproxalap is a potential new therapy for dry eye disease with a novel mechanism of action.

NOV03 (perfluorohexyloctane) is a first-in-class eye drop with a novel mechanism of action. If approved it will be the first to address signs and symptoms of dry eye disease.

In a study, both common and rare HMGCR variants were associated with an increased risk for cataract.

Regeneron is seeking an additional dosing regimen with a longer-term interval between doses. The PDUFA date is Feb. 28, 2023.

Xipere became commercially available in March 2022. It is the first therapy for patients with macular edema that provides a targeted delivery to the retina.

A biomarker used in kidney disease screening has potential to identify people with sight-threatening diabetic retinopathy.

Perfluorohexyloctane prevents excessive tear evaporation and has the ability to restores tear film balance. A new drug application is expected to be filed this year.

Byooviz, the first FDA approved ophthalmology biosimilar for macular degeneration, will be priced 40% lower than the reference product. It will be commercially available on July 1, 2022.

If approved, Orasis’ low-dose pilocarpine would be the second product that improves presbyopia, which is the age-related loss of clear up-close vision. The company plans to submit an NDA in the second half of the year.

Phase 3 trials show CSF-1, a low-dose pilocarpine, met clinical endpoints for improving presbyopia, or age-related blurry vision.